Why Imminent Orphan Status Designation Will Attract Big Pharma To Mast Therapeutics
- Likely positive orphan status opinion for MST-188 (for ALI) in EU next week provides imminent catalyst.
- Big pharma are actively acquiring and partnering with small biotechs treating sickle cell disease like MSTX.
- This week's setback by sickle cell disease competitor (GLYC) creates advantage for MSTX.
- Recent analyst opinion points to upside of 100%+ based on MSTX price target of $1.20.